uniQure N.V. Revenue from Contract with Customer, Excluding Assessed Tax
uniQure N.V. (QURE) reported Revenue from Contract with Customer, Excluding Assessed Tax of $3.56 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-05-05
- uniQure N.V. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $3.56M, a 127.31% increase year-over-year.
- uniQure N.V. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.57M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month |
|---|---|
| 2026-03-31 | $3.56M 10-Q · filed 2026-05-05 |
| 2025-03-31 | $1.57M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |